These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7534038)

  • 21. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress toward the structure and therapeutic use of the hairpin ribozyme.
    Earnshaw DJ; Gait MJ
    Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):403-11. PubMed ID: 9303192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled, targeted, intracellular expression of ribozymes: progress and problems.
    Rossi JJ
    Trends Biotechnol; 1995 Aug; 13(8):301-6. PubMed ID: 7544984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA.
    Kozu T; Sueoka E; Okabe S; Sueoka N; Komori A; Fujiki H
    J Cancer Res Clin Oncol; 1996; 122(4):254-6. PubMed ID: 8601580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential use of catalytic RNAs in therapy of HIV infection and other diseases.
    Rossi JJ; Cantin EM; Sarver N; Chang PF
    Pharmacol Ther; 1991; 50(2):245-54. PubMed ID: 1763136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ribozymes as human therapeutic agents.
    Christoffersen RE; Marr JJ
    J Med Chem; 1995 Jun; 38(12):2023-37. PubMed ID: 7783134
    [No Abstract]   [Full Text] [Related]  

  • 28. Ribozymes. Their functions and strategies for their use.
    Gibson SA; Shillitoe EJ
    Mol Biotechnol; 1997 Apr; 7(2):125-37. PubMed ID: 9219227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosterically controllable maxizymes for molecular gene therapy.
    Iyo M; Kawasaki H; Taira K
    Curr Opin Mol Ther; 2002 Apr; 4(2):154-65. PubMed ID: 12044037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribozyme- and deoxyribozyme-strategies for medical applications.
    Schubert S; Kurreck J
    Curr Drug Targets; 2004 Nov; 5(8):667-81. PubMed ID: 15578948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ribozymes: structure, characteristics and use as potential antiviral agents.
    Bartolomé J; Madejón A; Carreño V
    J Hepatol; 1995; 22(1 Suppl):57-64. PubMed ID: 7602079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDV ribozymes.
    Been MD
    Curr Top Microbiol Immunol; 2006; 307():47-65. PubMed ID: 16903220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for antiviral ribozymes and deoxyribozymes.
    Peracchi A
    Rev Med Virol; 2004; 14(1):47-64. PubMed ID: 14716691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA.
    Nosrati M; Li S; Bagheri S; Ginzinger D; Blackburn EH; Debs RJ; Kashani-Sabet M
    Clin Cancer Res; 2004 Aug; 10(15):4983-90. PubMed ID: 15297398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast.
    Castanotto D; Li H; Chow W; Rossi JJ; Deshler JO
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):1-13. PubMed ID: 9512091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ribozymes: applications to functional analysis and gene discovery.
    Shiota M; Sano M; Miyagishi M; Taira K
    J Biochem; 2004 Aug; 136(2):133-47. PubMed ID: 15496583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular ribozyme applications.
    Castanotto D; Li JR; Michienzi A; Langlois MA; Lee NS; Puymirat J; Rossi JJ
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):1140-5. PubMed ID: 12440991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.
    Dorai T; Olsson CA; Katz AE; Buttyan R
    Prostate; 1997 Sep; 32(4):246-58. PubMed ID: 9288183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases.
    Grassi G; Dawson P; Guarnieri G; Kandolf R; Grassi M
    Curr Pharm Biotechnol; 2004 Aug; 5(4):369-86. PubMed ID: 15320768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.